Oliver Lagore Vanvalin Investment Group’s CRISPR Therapeutics CRSP Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$2.55K	Buy	+75	New	+$2.9K	﹤0.01%	536
2024 Q4	$2.95K	Sell	75 -40	-35%	-$1.89K	﹤0.01%	554
2024 Q3	$5.4K	Hold	115	–	–	﹤0.01%	499
2024 Q2	$6.21K	Hold	115	–	–	﹤0.01%	469
2024 Q1	$7.84K	Hold	115	–	–	﹤0.01%	450
2023 Q4	$7.2K	Sell	115 -497	-81%	-$27.5K	﹤0.01%	470
2023 Q3	$27.8K	Sell	612 -203	-25%	-$10.5K	0.01%	308
2023 Q2	$45.8K	Hold	815	–	–	0.02%	261
2023 Q1	$36.9K	Sell	815 -200	-20%	-$9.71K	0.02%	218
2022 Q4	$41.3K	Sell	1,015 -1,050	-51%	-$55.7K	0.02%	198
2022 Q3	$135K	Sell	2,065 -300	-13%	-$21.7K	0.09%	103
2022 Q2	$144K	Buy	2,365 +1,200	+103%	+$70.5K	0.08%	107
2022 Q1	$74K	Buy	+1,165	New	+$73.2K	0.05%	153

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's CRSP Position: Q2 2025 in Review

Oliver Lagore Vanvalin Investment Group opened a new position in CRISPR Therapeutics (CRSP) in Q2 2025: 75 shares worth $2.55K. The stake represents ﹤0.01% of the portfolio and ranks #536 among its holdings. This is a return to the name: Oliver Lagore Vanvalin Investment Group previously reported a position in CRSP as recently as Q4 2024.

Oliver Lagore Vanvalin Investment Group first reported a position in CRSP in Q1 2022 and has held it in 13 quarters since. The position peaked at $144K in Q2 2022. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

Oliver Lagore Vanvalin Investment Group held 75 shares of CRISPR Therapeutics worth $2.55K as of Q2 2025.
CRISPR Therapeutics was a new Oliver Lagore Vanvalin Investment Group position in Q2 2025.
CRISPR Therapeutics made up ﹤0.01% of Oliver Lagore Vanvalin Investment Group's portfolio in Q2 2025, its #536 holding.
Oliver Lagore Vanvalin Investment Group first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 13 quarters since.
Oliver Lagore Vanvalin Investment Group's CRISPR Therapeutics position peaked at $144K in Q2 2022.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q2 2025, filed 10 Jul 2025.